Study: Improvement in glycemic parameters by adding dapagliflozin to metformin in T2D
New Rochelle, NY, October 1, 2018–Researchers used continuous glucose monitoring (CGM) to assess the effects of adding dapagliflozin to a regimen of either metformin or insulin in patients with type 2 diabetes (T2D) and found significant reductions in mean glucose and other glycemic factors, with greater improvements seen in patients taking metformin compared to insulin. The design and results of this trial are published in Diabetes Technology & Therapeutics (DTT), a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. Click here to read the full-text article free on the Diabetes Technology & Therapeutics (DTT) website.
CGM was used to determine daily variations in glucose during the week before patients received dapagliflozin and during the last week of treatment. Dapagliflozin is a U.S. FDA-approved inhibitor of sodium-glucose cotransporter 2 (SGLT2) and by blocking SGLT2 it increases urinary glucose excretion and improves glucose control. CGM was able to show the effects of adding dapagliflozin to either metformin or insulin in terms of overall mean glucose concentration, fasting plasma glucose, postprandial glucose, time spent in the target glucose range, and glucose variability.
The article entitled "Effects of Dapagliflozin on 24-Hour Glycemic Control in Patients with Type 2 Diabetes: A Randomized Controlled Trial," was coauthored by Robert Henry, MD, University of California San Diego School of Medicine and colleagues from UC San Diego School of Medicine, Integrated Medical Development (Princeton Junction, NJ), Medpace (Cincinnati, OH), and AstraZeneca (Fort Washington, PA).
"["As we move beyond A1c to measure glucose control, the use of CGM is becoming more important especially in insulin-requiring patients with diabetes. Time in range (TIR) and other metrics to measure glucose variability may closely relate with a patient's overall glucose control," says DTT Editor-in-Chief Satish Garg, MD, Professor of Medicine and Pediatrics at the University of Colorado Denver (Aurora). "Henry and colleagues emphasize the importance of adding an SGLT2 inhibitor on different metrics of glucose control as measured by CGM."
About the Journal
Diabetes Technology & Therapeutics (DTT) is a monthly peer-reviewed journal that covers new technology and new products for the treatment, monitoring, diagnosis, and prevention of diabetes and its complications. Led by Editor-in-Chief Satish Garg, MD, the Journal covers topics that include noninvasive glucose monitoring, implantable continuous glucose sensors, novel routes of insulin administration, genetic engineering, the artificial pancreas, measures of long-term control, computer applications for case management, telemedicine, the Internet, and new medications. Tables of contents and a free sample issue may be viewed on the Diabetes Technology & Therapeutics (DTT) website. DTT is the official journal of the International Conference on Advanced Technologies & Treatments for Diabetes (ATTD).
The International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) presents top caliber scientific programs that have provided participants with cutting-edge research and analysis into the latest developments in diabetes-related technology. A unique and innovative conference, ATTD brings the world's leading researchers and clinicians together for a lively exchange of ideas and information related to the technology, treatment, and prevention of diabetes and related illnesses.
About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Thyroid, Metabolic Syndrome and Related Disorders, Journal of Aerosol Medicine and Pulmonary Drug Delivery, Childhood Obesity, and Population Health Management. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News ), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.